Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the In...
The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enz...
US$3.2 million (A$4.8m) R&D tax incentive rebate received from Australian Tax Office and XanaMIA Ph...
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising s...
Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years a...
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising s...
A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical tria...
Exploring Xanamem® and the "cortisol hypothesis" for more than 6 million Americans suffering from A...
Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1] which is commonly ass...
Clinical Dementia Rating Scale - Sum of Boxes effect of 0.6 to 0.8 points observed in patients with...